Opinion|Videos|August 1, 2024
Importance of Patient-Reported Outcomes
Author(s)Steven D. Nathan, MD
Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the potential impact of these novel treatments on disease progression, mortality, and patient-reported outcomes such as quality of life, survival time, and functional status?
- An important consideration in drug development is understanding the impact on patient-reported outcomes and quality of life. How are the clinical trials for idiopathic pulmonary fibrosis agents incorporating these measures?
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5